Serum Autoreactivity Predicts Time to Response to Omalizumab Therapy in Chronic Spontaneous Urticaria

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2016.07.047
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy

Acta Dermato-Venereologica
DermatologyMedicine
2017English

Omalizumab Treatment in Patients With Chronic Spontaneous Urticaria

Bőrgyógyászati és Venerológiai Szemle
2015English

The Efficacy of Omalizumab Therapy in Chronic Spontaneous Urticaria: A Retrospective Analysis

Turkderm Deri Hastaliklari ve Frengi Arsivi
DermatologyInfectious Diseases
2019English

Efficacy of Omalizumab in Treatment-Resistant Chronic Spontaneous Urticaria

Asim, Allerji, Immunoloji
Respiratory MedicinePulmonaryAllergyImmunology
2018English

Effects of Omalizumab on Chronic Urticaria Not Responding to Recommended Therapy

Allergy, Asthma and Clinical Immunology
ImmunologyPulmonaryAllergyRespiratory Medicine
2012English

Clinical Management of Urticaria Using Omalizumab: The First Licensed Biological Therapy Available for Chronic Spontaneous Urticaria

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2016English

Transient Hair Loss in Patients With Chronic Spontaneous Urticaria Treated With Omalizumab

European Annals of Allergy and Clinical Immunology
AllergyImmunology
2017English

Omalizumab in Chronic Urticaria: A Comprehensive Review

Turkderm Deri Hastaliklari ve Frengi Arsivi
DermatologyInfectious Diseases
2018English

Omalizumab Updosing Allows Disease Activity Control in Refractory Patients With Chronic Spontaneous Urticaria

British Journal of Dermatology
DermatologyMedicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy